The FDA has approved intranasal etripamil (Cardamyst; Milestone Pharmaceuticals) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT), making it the first self-administered, ...
Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.
Standard treatments for slow heart rate which include atropine administration and external pacing will not produce effective results because doctors must first identify the cardiac cycle. The kidneys ...
MANILA, Philippines — Metro Pacific Investments Corp. (MPIC)’s digital health care arm mWell is further advancing its position in the digital health space with its latest innovation that enables ...
SANTA CLARA, Calif., December 10, 2025--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, ...
HeartBeam BEAT recently secured FDA 510(k) clearance for its first-of-its-kind, cable-free synthesized 12-lead ECG technology, marking a major inflection point in the company’s mission to modernize ...
HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback